Similarly, oxaliplatin, also clinically used for TACE, has been shown to promote ICD in vitro and to induce DC maturation as well as increase CD8+ T cells in an HCC inoculation mouse model (129). The gene discussed is CD8A; the disease is hepatocellular carcinoma.